To ask the Secretary of State for Health and Social Care, what plans his Department has to increase access to cannabis based medicines for people with multiple sclerosis.
This answer is the replacement for a previous holding answer.
25 February 2021
The licensed cannabis-based medicine Sativex, for the treatment of spasticity in people with multiple sclerosis, is available for prescribing on the National Health Service in England, where clinically appropriate. This follows clear demonstrated evidence of safety and clinical and cost effectiveness.
We continue to work hard with the health system, industry and researchers to improve the evidence base for other cannabis-based medicines and to implement the recommendations of NHS England and NHS Improvement’s review on barriers to accessing unlicensed cannabis based medicinal products. This includes the design of clinical trials and the establishment of a national patient registry.